Opportunity radar
4,186,134 patents indexed · 165,974,948 citations · issued 2005-01-04 → 2026-05-05
Showing50 of 25,005
Pharma (A61K)Therapy methods (A61P)Med devices (A61M)Agriculture (A01)Hand tools (B25)Consumer (A47)Energy (H01M)AI / ML (G06N)
| Patent # | Title | Assets | Issued | Expires | Fwd cites | Score |
|---|---|---|---|---|---|---|
| 12528864 | Antigen binding proteins | 🖼🧊📄§ | 2026-01-20 | 2042-09-02 | 0 | 31 |
| 12527823 | Generation of kidney glomerular specific endothelial cells and methods of use | 🖼🧊📄§ | 2026-01-20 | 2040-11-20 | 0 | 31 |
| 12528868 | CD1a antibodies and uses thereof | 🖼🧊📄§ | 2026-01-20 | 2043-07-19 | 0 | 31 |
| 12528775 | Oxygenated and amino- or ammonium-containing phosphonic acid derivatives and their medical use | 🖼🧊📄§ | 2026-01-20 | 2042-09-26 | 0 | 31 |
| 12528863 | Claudin-6 binding molecules and uses thereof | 🖼🧊📄§ | 2026-01-20 | 2040-07-10 | 0 | 31 |
| 12527837 | Peptide for use in the prevention and/or treatment of a disease caused by a virus affecting the respiratory tract | 🖼🧊📄§ | 2026-01-20 | 2041-05-19 | 0 | 31 |
| 12527799 | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders | 🖼🧊📄§ | 2026-01-20 | 2043-09-07 | 0 | 31 |
| 12527806 | Composition for preventing or treating diabetes mellitus | 🖼🧊📄§ | 2026-01-20 | 2042-08-17 | 0 | 31 |
| 12527879 | Ligands targeted to epidermal growth factor receptors and compositions for use in treating tumors | 🖼🧊📄§ | 2026-01-20 | 2040-05-31 | 0 | 31 |
| 12527782 | Use of hexokinase 2/mitochondria-detaching compounds for treating hexokinase-2 (HK2)-expressing cancers | 🖼🧊📄§ | 2026-01-20 | 2042-01-25 | 0 | 31 |
| 12527870 | Peptide hydrogels for delivery of immunosuppressive drugs and uses thereof | 🖼🧊📄§ | 2026-01-20 | 2039-05-03 | 0 | 31 |
| 12527827 | Compositions for preventing or treating cancer comprising extracts of Asarum maculatum nakai | 🖼🧊📄§ | 2026-01-20 | 2042-10-07 | 0 | 31 |
| 12527858 | MVA vectors for expressing multiple cytomegalovirus (CMV) antigens and use thereof | 🖼🧊📄§ | 2026-01-20 | 2040-11-11 | 0 | 31 |
| 12528839 | Conjugated virus-like particles and uses thereof as anti-tumor immune redirectors | 🖼🧊📄§ | 2026-01-20 | 2042-08-15 | 0 | 31 |
| 12529037 | M1 virus mutant and use thereof | 🖼🧊📄§ | 2026-01-20 | 2040-05-31 | 0 | 31 |
| 12527821 | Compositions and methods related to tumor cell killers and vaccines | 🖼🧊📄§ | 2026-01-20 | 2039-05-15 | 0 | 31 |
| 12527856 | Artificial RNA molecules encoding a norovirus antigen and uses thereof | 🖼🧊📄§ | 2026-01-20 | 2044-11-07 | 0 | 31 |
| 12528879 | Multi-specific binding proteins for cancer treatment | 🖼🧊📄§ | 2026-01-20 | 2043-06-01 | 0 | 31 |
| 12528851 | IL2-based therapeutics and methods of use thereof | 🖼🧊📄§ | 2026-01-20 | 2042-06-13 | 0 | 31 |
| 12527770 | Methods of managing pain using dexmedetomidine transdermal delivery devices | 🖼🧊📄§ | 2026-01-20 | 2037-10-31 | 0 | 31 |
| 12527816 | Sodium chlorite compositions with enhanced anti-microbial efficacy and reduced toxicity | 🖼🧊📄§ | 2026-01-20 | 2043-07-07 | 0 | 31 |
| 12528836 | Dosing regimens | 🖼🧊📄§ | 2026-01-20 | 2043-12-21 | 0 | 31 |
| 12527883 | Retinal promoter and uses thereof | 🖼🧊📄§ | 2026-01-20 | 2038-09-03 | 0 | 31 |
| 12527688 | Dissolvable medical device for drugs delivery | 🖼🧊📄§ | 2026-01-20 | 2042-12-22 | 0 | 31 |
| 12527875 | Methods for treating graft versus host disease | 🖼🧊📄§ | 2026-01-20 | 2041-02-19 | 0 | 31 |
| 12528840 | Transcription active complex targeting cancer drug from viral protein sequence | 🖼🧊📄§ | 2026-01-20 | 2041-10-21 | 0 | 31 |
| 12527979 | Treatment of HER3-mutated cancer by administration of anti-HER3 antibody-drug conjugate | 🖼🧊📄§ | 2026-01-20 | 2039-09-19 | 0 | 31 |
| 12527753 | Cysteamine for the treatment, mitigation and prevention of coronaviral, e.g., SARS-CoV-2, infections | 🖼🧊📄§ | 2026-01-20 | 2041-09-15 | 0 | 31 |
| 12527755 | Formulations containing acetaminophen and sulfoalkyl ether cyclodextrin | 🖼🧊📄§ | 2026-01-20 | 2037-09-15 | 0 | 31 |
| 12527773 | Flavi-block: a pan-flavivirus inhibitor | 🖼🧊📄§ | 2026-01-20 | 2040-10-15 | 0 | 31 |
| 12528817 | Method of inhibiting kinase by mesylate salts of triazolopyrazine derivatives | 🖼🧊📄§ | 2026-01-20 | 2043-12-26 | 0 | 31 |
| 12527754 | Methods and compositions for preventing and treating metabolic syndrome induced by antipsychotic treatment and related diseases and conditions | 🖼🧊📄§ | 2026-01-20 | 2039-06-28 | 0 | 31 |
| 12528768 | Crystalline form of a 7H-benzo[7]annulene-2-carboxylic acid derivative | 🖼🧊📄§ | 2026-01-20 | 2040-12-08 | 0 | 31 |
| 12527876 | Insulin-like growth factor-chemotherapeutic conjugate for treating myelodysplastic syndrome | 🖼🧊📄§ | 2026-01-20 | 2042-03-24 | 0 | 31 |
| 12527772 | Pharmaceutical combination comprising ponesimod | 🖼🧊📄§ | 2026-01-20 | 2043-06-27 | 0 | 31 |
| 12521442 | ASH1L inhibitors and methods of treatment therewith | 🖼🧊📄§ | 2026-01-13 | 2043-12-05 | 0 | 31 |
| 12521402 | Biomarker and drug combinations for heart failure prediction | 🖼🧊📄§ | 2026-01-13 | 2043-09-21 | 0 | 31 |
| 12521373 | Use of losartan for the treatment of fibrotic diseases, in particular epidermolysis bullosa | 🖼🧊📄§ | 2026-01-13 | 2040-12-14 | 0 | 31 |
| 12521382 | 3-(hydroxy)-pyridin-4(1H)-one compounds and methods of making and using the same | 🖼🧊📄§ | 2026-01-13 | 2045-05-08 | 0 | 31 |
| 12522666 | CD22 targeting-moiety for the treatment of B-cell acute lymphoblastic leukemia (B-ALL) | 🖼🧊📄§ | 2026-01-13 | 2041-03-11 | 0 | 31 |
| 12521447 | Cationic lipid compositions for tissue-specific delivery | 🖼🧊📄§ | 2026-01-13 | 2041-07-16 | 0 | 31 |
| 12522636 | Compositions and methods for delivering CFTR polypeptides | 🖼🧊📄§ | 2026-01-13 | 2040-11-06 | 0 | 31 |
| 12521410 | Compounds and pharmaceutical uses thereof | 🖼🧊📄§ | 2026-01-13 | 2043-10-24 | 0 | 31 |
| 12522596 | Compounds as GLP-1R agonists | 🖼🧊📄§ | 2026-01-13 | 2045-01-13 | 0 | 31 |
| 12522661 | CD28 single domain antibodies and multivalent and multispecific constructs thereof | 🖼🧊📄§ | 2026-01-13 | 2041-01-28 | 0 | 31 |
| 12522658 | Anti-CD79 chimeric antigen receptors, CAR-T cells, and uses thereof | 🖼🧊📄§ | 2026-01-13 | 2040-11-17 | 0 | 31 |
| 12521393 | Cytotoxicity targeting chimeras for CCR2-expressing cells | 🖼🧊📄§ | 2026-01-13 | 2044-02-09 | 0 | 31 |
| 12521398 | Composition for treating synucleinopathies | 🖼🧊📄§ | 2026-01-13 | 2040-12-16 | 0 | 31 |
| 12521378 | Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans | 🖼🧊📄§ | 2026-01-13 | 2042-04-28 | 0 | 31 |
| 12522562 | Intestine-specific partial agonists of farnesoid X receptor and uses thereof | 🖼🧊📄§ | 2026-01-13 | 2043-06-26 | 0 | 31 |